Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?

Bristol Myers Squibb is due to report Q3 2026 results on Oct. 29; consensus estimates are $12.56 billion in sales and $1.28 per share in earnings. Growth drugs and an increased Eliquis revenue-growth outlook of 20–25%, up from 10–15%, may offset declines in legacy products, but the earnings estimate for 2026 has fallen to $6.51 from $6.91 and the company’s negative 15.06% Earnings ESP weighs on the pre-report outlook. The article cites pipeline potential and a 4.1% dividend yield, while flagging rising debt; it recommends prospective investors wait and existing shareholders hold.

Analysis

The setup is asymmetric around execution, not simply an earnings beat: past beats offer limited reassurance when 2026 EPS estimates have been cut and the cited earnings-surprise model is negative. A clean headline could still fail to lift BMY if legacy erosion absorbs growth-drug gains or management trims full-year expectations. Conversely, investors may be underweighting how much sustained Eliquis demand can cushion the near-term revenue bridge, but BMY shares only capture part of that franchise’s economics alongside PFE; do not treat reported Eliquis sales as equivalent to BMY earnings growth.

For the next few days, estimate revisions and guidance matter more than a modest beat against consensus. Over 1–3 months, watch growth-drug uptake against declines in legacy products, and whether productivity savings support margins without masking weak underlying sales. Over 6–18 months, pipeline success could improve the replacement narrative, but debt makes the payoff less forgiving: execution delays or weaker cash generation could pressure equity value and the dividend’s perceived safety. The recent share outperformance and premium to BMY’s own historical P/E reduce the margin for disappointment, even though the valuation remains below the cited large-cap pharma average.

The contrarian risk is that “safe-haven” framing overweights the dividend and underweights a multi-year portfolio transition. We lack current option pricing, balance-sheet maturity detail, and independent product-level growth data, so there is no basis for an options trade or a precise valuation target. The thesis improves if guidance and cash flow hold while newer drugs scale; it weakens on another EPS reduction, deteriorating debt metrics, or growth-product gains failing to offset legacy declines.

Key Decisions for Investors

• Before the Oct. 29 release: avoid adding outright BMY exposure; the estimate-revision direction and negative surprise indicator make pre-event upside less compelling than the headline beat record suggests.
• Existing holders: maintain a measured position rather than automatically selling for the event, but size exposure for a guidance-driven gap risk. Reassess after the call using full-year EPS guidance, operating cash generation, and the balance-sheet outlook.
• Post-event entry alert: consider adding only if management sustains its outlook and reported growth-product momentum offsets legacy erosion. A revenue beat without stable guidance or cash conversion is not sufficient confirmation.
• Relative-value watch: compare BMY and PFE responses to Eliquis commentary, but do not assume identical earnings sensitivity; verify each company’s disclosed economics and guidance before putting on a pair.